Search

Displaying results 911 - 920 of 2435 in total
  1. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  2. Drug

    Gliquidone

    go.drugbank.com/drugs/DB01251
    Approved

    Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, an...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  3. Drug

    Ergometrine

    go.drugbank.com/drugs/DB01253
    ApprovedInvestigational

    An ergot alkaloid with uterine and vascular smooth muscle contractile properties.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  4. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication ...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  5. Drug

    Darunavir

    go.drugbank.com/drugs/DB01264
    ApprovedInvestigational

    Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to...

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  6. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Aust...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Oxtriphylline

    go.drugbank.com/drugs/DB01303
    Approved

    Oxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse i...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  9. Drug

    Hexobarbital

    go.drugbank.com/drugs/DB01355
    Experimental

    A barbiturate that is effective as a hypnotic and sedative.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  10. Drug

    Rasagiline

    go.drugbank.com/drugs/DB01367
    ApprovedInvestigational

    Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates